Close Menu

skin cancer

The company said it intends to use the net proceeds from the offering to fund further commercialization of its clinical tests, among other uses.

Along with significantly mutated genes across cutaneous melanoma cases, researchers saw loss-of-function mutations in the X chromosome gene DDX3X in tumors from male patients.

An analysis of pediatric cancer survivors suggests subsequent neoplasm risk can increase after certain genotoxic treatments in those with DNA repair gene changes.

Researchers used case and control genotypes alongside related trait, transcriptome, and population data to identify 85 cutaneous melanoma candidate loci.

The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.

The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma. 

The new project will be the second stage of the QSkin study, which has documented the disease in 44,000 Australians and developed a melanoma risk predictor.

The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.

The company markets two tests for skin cancer, including DecisionDx-Melanoma for identifying high-risk Stage I and II cutaneous melanoma patients.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.